Previous 10 | Next 10 |
4 Penny Stocks To Watch Right Now Whether you’re a beginning investor or a seasoned professional, penny stocks have a lot to offer. To start, penny stocks are simply any that trade below the $5 mark. With this broad categorization, there are plenty of penny stocks to wa...
5 Penny Stocks To Buy According To Analysts This week kicked off another busy week for penny stocks and small-caps. Not only did we see a plethora of energy stocks surge during early market hours, but biotech was also a core focus. Meanwhile, the broader markets are trying to re...
InflaRx ([[IFRX]] +12.7%) jumps on a 5x surge in volume in apparent reaction to results from the first portion of a Phase 2/3 clinical trial, PANAMO, in the Netherlands evaluating lead candide IFX-1 plus best supportive care ((BSC)) in severely ill hospitalized adult COVID-19 patients. The da...
InflaRx (NASDAQ: IFRX ) -4% announced Thomas Taapken as CFO, effective October 1. More news on: InflaRx N.V., Healthcare stocks news, Read more ...
Thomas Taapken, Ph.D. appointed Chief Financial Officer Jordan Zwick promoted to Chief Strategy Officer JENA, Germany, Sept. 17, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the compl...
Immunomedics (NASDAQ: IMMU ) +106% after Gilead to buy the company for $21B (~$88/share). More news on: Immunomedics, Inc., Cassava Sciences, Inc., China Natural Resources, Inc., , Stocks on the move, Read more ...
InflaRx (NASDAQ: IFRX ) has commenced global Phase 3 part of its Phase 2/3 trial with IFX-1 in severe COVID-19 induced pneumonia with the initiation of the first site in the Netherlands. Also the German regulatory authority, has approved the Phase 3 trial. More news on: InflaRx N....
First site initiated for enrollment in the Netherlands Regulatory approval granted to start trial in Germany Additional sites to be added in the US, EU and other regions Encouraging Phase II data accepted for publication in The Lancet Rheumatology JENA, Germany, Sept. 14, 2020 (GLOBE...
JENA, Germany, Aug. 06, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present at several upcoming virtual investor events in August and September as follows:...
Announced encouraging results from the Phase II portion of the Phase II/III adaptive, randomized, controlled trial in patients with COVID-19 induced pneumonia, showing a trend in lower 28-day all-cause mortality rate Completed end-of-Phase II meeting with the FDA for IFX-1 in hidradeniti...
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...